PolyBio Research Foundation
@polybiorf.bsky.social
501(c)3 transforming how #LongCovid, #ME/CFS & Lyme+ are studied, diagnosed, and treated. Leading the #LongCovid Research Consortium.
Pinned
1/ Introducing PolyBio’s new interactive website module, where you can learn about our #LongCovid Research Consortium projects, technologies, and findings across international institutions:
polybio.org/consortium-p...
polybio.org/consortium-p...
One of our favourite highlights of the year at PolyBio: Dr. Amy Proal’s TedX talk on the pathogen drivers of human aging.
“As [chronic pathogens] live in us, they can create proteins & products that actively distort the signalling of our own human genes.”
#polybio2026countdown
“As [chronic pathogens] live in us, they can create proteins & products that actively distort the signalling of our own human genes.”
#polybio2026countdown
December 26, 2025 at 8:28 PM
One of our favourite highlights of the year at PolyBio: Dr. Amy Proal’s TedX talk on the pathogen drivers of human aging.
“As [chronic pathogens] live in us, they can create proteins & products that actively distort the signalling of our own human genes.”
#polybio2026countdown
“As [chronic pathogens] live in us, they can create proteins & products that actively distort the signalling of our own human genes.”
#polybio2026countdown
A key contribution to the field this year by Dr. Amy Proal, PolyBio President & CEO, was her LA Times Op-Ed—a call-to-arms to both government agencies and private organizations to support Long Covid clinical trials.
www.latimes.com/opinion/stor...
#polybio #polybio2026countdown
www.latimes.com/opinion/stor...
#polybio #polybio2026countdown
December 23, 2025 at 12:20 AM
A key contribution to the field this year by Dr. Amy Proal, PolyBio President & CEO, was her LA Times Op-Ed—a call-to-arms to both government agencies and private organizations to support Long Covid clinical trials.
www.latimes.com/opinion/stor...
#polybio #polybio2026countdown
www.latimes.com/opinion/stor...
#polybio #polybio2026countdown
Looking back at some of PolyBio’s most influential moments of 2025–we can’t forget about this collaborative effort between Dr. Iwasaki’s Yale team & Dr. Bragée’s ME/CFS clinic in Sweden. The PolyBio-supported study used cerebrospinal fluid to identify 2 distinct ME/CFS subtypes.
December 20, 2025 at 8:29 PM
Looking back at some of PolyBio’s most influential moments of 2025–we can’t forget about this collaborative effort between Dr. Iwasaki’s Yale team & Dr. Bragée’s ME/CFS clinic in Sweden. The PolyBio-supported study used cerebrospinal fluid to identify 2 distinct ME/CFS subtypes.
Next up in PolyBio’s influential moments of 2025: we began supporting a clinical trial of low-dose Rapamycin for Long Covid at NYC’s Mount Sinai CoRE clinic. The ongoing study is assessing how patients’ immune markers (i.e. T-cell function) change over time. #polybio2026countdown
December 19, 2025 at 7:21 PM
Next up in PolyBio’s influential moments of 2025: we began supporting a clinical trial of low-dose Rapamycin for Long Covid at NYC’s Mount Sinai CoRE clinic. The ongoing study is assessing how patients’ immune markers (i.e. T-cell function) change over time. #polybio2026countdown
Breaking: PolyBio joins HHS Lyme Disease roundtable meeting, as new clinical trial advances treatment for Chronic Babesiosis
This week, PolyBio President Dr. Amy Proal attended a U.S. Department of Health and Human Services–convened Lyme Disease roundtable meeting. 🧵
This week, PolyBio President Dr. Amy Proal attended a U.S. Department of Health and Human Services–convened Lyme Disease roundtable meeting. 🧵
December 18, 2025 at 11:37 PM
Breaking: PolyBio joins HHS Lyme Disease roundtable meeting, as new clinical trial advances treatment for Chronic Babesiosis
This week, PolyBio President Dr. Amy Proal attended a U.S. Department of Health and Human Services–convened Lyme Disease roundtable meeting. 🧵
This week, PolyBio President Dr. Amy Proal attended a U.S. Department of Health and Human Services–convened Lyme Disease roundtable meeting. 🧵
Today at the HHS Invisible Illness roundtable: Dr. Amy Proal (PolyBio President & Scientific Director of the CoRE clinic) with 60 Degrees Pharma CEO, Dr. Geoffrey Dow. Dr.s Proal & Dow were part of the crucial discussion to address gaps in Lyme disease diagnostics & treatment.
December 17, 2025 at 12:27 AM
Today at the HHS Invisible Illness roundtable: Dr. Amy Proal (PolyBio President & Scientific Director of the CoRE clinic) with 60 Degrees Pharma CEO, Dr. Geoffrey Dow. Dr.s Proal & Dow were part of the crucial discussion to address gaps in Lyme disease diagnostics & treatment.
PolyBio collaborators joined forces last week at a think tank meeting on pathogenic persistence biomarkers. The discussion focused on accessible biomarkers which showed promise for detecting chronic infections hidden in tissues.
These included immune biosensors, extracellular vesicles, and more.
These included immune biosensors, extracellular vesicles, and more.
Thank you to the experts at Banbury last week for insightful discussions on “Accessible Biomarkers of Pathogen Tissue Persistence.” Special thanks to organizers Drs. Amy Proal, Michael VanElzakker, Shannon Stott, and John Wherry, and to @polybiorf.bsky.social for funding.
Agenda: bit.ly/PERSIST-25
Agenda: bit.ly/PERSIST-25
December 16, 2025 at 10:51 PM
PolyBio collaborators joined forces last week at a think tank meeting on pathogenic persistence biomarkers. The discussion focused on accessible biomarkers which showed promise for detecting chronic infections hidden in tissues.
These included immune biosensors, extracellular vesicles, and more.
These included immune biosensors, extracellular vesicles, and more.
One of PolyBio’s most notable moments of 2025 was the publication of the ‘Long Covid Roadmaps paper,’ which brought together 30+ global experts. The paper was the first of its kind, discussing treatment strategies targeting the SARS-CoV-2 viral reservoir in Long Covid.
#polybio2026countdown
#polybio2026countdown
December 16, 2025 at 4:42 PM
One of PolyBio’s most notable moments of 2025 was the publication of the ‘Long Covid Roadmaps paper,’ which brought together 30+ global experts. The paper was the first of its kind, discussing treatment strategies targeting the SARS-CoV-2 viral reservoir in Long Covid.
#polybio2026countdown
#polybio2026countdown
We’re counting down to the new year in the best way we know how: by looking back at 12 of PolyBio’s most influential moments of 2025. Follow along with us to recap key research in the complex chronic illness space this year. #polybio2026countdown
December 15, 2025 at 4:24 PM
We’re counting down to the new year in the best way we know how: by looking back at 12 of PolyBio’s most influential moments of 2025. Follow along with us to recap key research in the complex chronic illness space this year. #polybio2026countdown
We are excited to announce that PolyBio core team members Dr. Amy Proal & Dr. David Putrino are leading a clinical trial of tafenoquine for treatment of chronic babesiosis, in partnership with 60 Degrees Pharma. The trial will take place at Mount Sinai’s CoRE clinic & will treat up to 100 patients.
December 14, 2025 at 10:40 PM
We are excited to announce that PolyBio core team members Dr. Amy Proal & Dr. David Putrino are leading a clinical trial of tafenoquine for treatment of chronic babesiosis, in partnership with 60 Degrees Pharma. The trial will take place at Mount Sinai’s CoRE clinic & will treat up to 100 patients.
1/ PolyBio supports research & treatment for children with Long COVID. This year, a study by our team at Harvard Medical School found that neutrophil immune cells from children with Long Covid were hyperactive and associated with pro-inflammatory pathway signaling.
December 12, 2025 at 7:04 PM
1/ PolyBio supports research & treatment for children with Long COVID. This year, a study by our team at Harvard Medical School found that neutrophil immune cells from children with Long Covid were hyperactive and associated with pro-inflammatory pathway signaling.
How PolyBio is driving forward ME/CFS research🧵
In 2025, PolyBio’s cofounders helped identify biomarkers that divide ME/CFS patients into two subgroups. One group had elevated MMPs/cytokines consistent with CNS inflammation; the other showed unique immune correlations linked to joint hypermobility.
In 2025, PolyBio’s cofounders helped identify biomarkers that divide ME/CFS patients into two subgroups. One group had elevated MMPs/cytokines consistent with CNS inflammation; the other showed unique immune correlations linked to joint hypermobility.
December 11, 2025 at 1:53 AM
How PolyBio is driving forward ME/CFS research🧵
In 2025, PolyBio’s cofounders helped identify biomarkers that divide ME/CFS patients into two subgroups. One group had elevated MMPs/cytokines consistent with CNS inflammation; the other showed unique immune correlations linked to joint hypermobility.
In 2025, PolyBio’s cofounders helped identify biomarkers that divide ME/CFS patients into two subgroups. One group had elevated MMPs/cytokines consistent with CNS inflammation; the other showed unique immune correlations linked to joint hypermobility.
“We sought out Amy & PolyBio because we cannot afford less than the best knowledge & information to help guide our [mAb trials],” said Invivyd chairman Marc Elia. PolyBio has funded 4+ clinical trials & most recently is supporting sample analysis for a RCT of Anktiva in Long Covid.
December 10, 2025 at 6:37 PM
“We sought out Amy & PolyBio because we cannot afford less than the best knowledge & information to help guide our [mAb trials],” said Invivyd chairman Marc Elia. PolyBio has funded 4+ clinical trials & most recently is supporting sample analysis for a RCT of Anktiva in Long Covid.
PolyBio and WE&ME supported study identifies two distinct ME/CFS subtypes
🧪Collaborative research uncovers immune and biomarker patterns that could help subclassify ME/CFS and guide future treatments.
polybio.org/polybio-and-...
🧪Collaborative research uncovers immune and biomarker patterns that could help subclassify ME/CFS and guide future treatments.
polybio.org/polybio-and-...
May 20, 2025 at 3:27 PM
PolyBio and WE&ME supported study identifies two distinct ME/CFS subtypes
🧪Collaborative research uncovers immune and biomarker patterns that could help subclassify ME/CFS and guide future treatments.
polybio.org/polybio-and-...
🧪Collaborative research uncovers immune and biomarker patterns that could help subclassify ME/CFS and guide future treatments.
polybio.org/polybio-and-...
PolyBio’s Spring Symposium is approaching fast—on May 16, watch exciting project updates on clinical trials, tissue pipelines, immune & metabolism findings on infection-associated chronic illnesses.
Sign up now: us02web.zoom.us/webinar/regi...
Sign up now: us02web.zoom.us/webinar/regi...
May 8, 2025 at 12:09 AM
PolyBio’s Spring Symposium is approaching fast—on May 16, watch exciting project updates on clinical trials, tissue pipelines, immune & metabolism findings on infection-associated chronic illnesses.
Sign up now: us02web.zoom.us/webinar/regi...
Sign up now: us02web.zoom.us/webinar/regi...
Post-treatment Lyme Disease patients with chronic pain in the US—consider participating in this decentralized study (completely virtual). It’s run via the CoRE clinic under the direction of Drs. David Putrino and Amy Proal @putrinolab.bsky.social @coresinai.bsky.social
May 2, 2025 at 3:21 PM
Post-treatment Lyme Disease patients with chronic pain in the US—consider participating in this decentralized study (completely virtual). It’s run via the CoRE clinic under the direction of Drs. David Putrino and Amy Proal @putrinolab.bsky.social @coresinai.bsky.social
The PolyBio-supported study on elevated plasma proteins associated with breathlessness in Long COVID was featured in an article in Technology Networks : www.technologynetworks.com/tn/news/long...
May 1, 2025 at 4:48 PM
The PolyBio-supported study on elevated plasma proteins associated with breathlessness in Long COVID was featured in an article in Technology Networks : www.technologynetworks.com/tn/news/long...
Calling all Long Covid, ME/CFS and Post-Treatment Lyme patients in the Boston area! This PolyBio-supported study is now seeking participants.
Participants must be able to attend an in-person visit at Brigham & Women’s hospital in Boston to participate.
Email dsaadi@mgh.harvard.edu if interested
Participants must be able to attend an in-person visit at Brigham & Women’s hospital in Boston to participate.
Email dsaadi@mgh.harvard.edu if interested
April 18, 2025 at 6:09 PM
Calling all Long Covid, ME/CFS and Post-Treatment Lyme patients in the Boston area! This PolyBio-supported study is now seeking participants.
Participants must be able to attend an in-person visit at Brigham & Women’s hospital in Boston to participate.
Email dsaadi@mgh.harvard.edu if interested
Participants must be able to attend an in-person visit at Brigham & Women’s hospital in Boston to participate.
Email dsaadi@mgh.harvard.edu if interested
We’re truly excited that the PolyBio supported Low-dose Rapamycin trial is now recruiting in the NYC area.
Interested in learning more? Here’s the full study summary: polybio.org/projects/lon...
Interested in learning more? Here’s the full study summary: polybio.org/projects/lon...
April 15, 2025 at 3:16 PM
We’re truly excited that the PolyBio supported Low-dose Rapamycin trial is now recruiting in the NYC area.
Interested in learning more? Here’s the full study summary: polybio.org/projects/lon...
Interested in learning more? Here’s the full study summary: polybio.org/projects/lon...
BREAKING: Development of a spike protein-specific radiolabeled antibody used with PET imaging shows presence of spike in brain & lungs of macaque monkeys 3 months post-COVID; provides new viral reservoir detection opportunity for long COVID: www.nature.com/articles/s41...
Whole-body visualization of SARS-CoV-2 biodistribution in vivo by immunoPET imaging in non-human primates - Nature Communications
There are limited approaches to monitor virus spread in vivo. Here, the authors report PET/CT-based in vivo imaging to track SARS-CoV-2 biodistribution in a COVID-19 non-human primate model using a ra...
www.nature.com
March 28, 2025 at 6:13 PM
BREAKING: Development of a spike protein-specific radiolabeled antibody used with PET imaging shows presence of spike in brain & lungs of macaque monkeys 3 months post-COVID; provides new viral reservoir detection opportunity for long COVID: www.nature.com/articles/s41...
Dr. Rigel Chan is investigating SARS-CoV-2’s impact on the development of #Alzheimers. His work has found that S protein levels in cells aren’t associated with AD, “but exposure to antigens like Spike may alter the conditions such that [patients] become more susceptible to HSV1.”
March 21, 2025 at 7:13 PM
Dr. Rigel Chan is investigating SARS-CoV-2’s impact on the development of #Alzheimers. His work has found that S protein levels in cells aren’t associated with AD, “but exposure to antigens like Spike may alter the conditions such that [patients] become more susceptible to HSV1.”
Dr. Zian Tseng has been studying sudden cardiac deaths since 2011–and is now using those data to compare to SCDs post-COVID. “A post-2020 person who recovered from COVID… died suddenly from their acute myocardial infarction. We found SARS-CoV-2 Spike RNA in their brain [tissue].”
March 18, 2025 at 8:45 PM
Dr. Zian Tseng has been studying sudden cardiac deaths since 2011–and is now using those data to compare to SCDs post-COVID. “A post-2020 person who recovered from COVID… died suddenly from their acute myocardial infarction. We found SARS-CoV-2 Spike RNA in their brain [tissue].”
Dr. David Price is investigating the role of lung dysfunction in Long Covid: “We’re sampling bronchoalveolar lavage fluid and transbronchial biopsies… what we plan to do is metagenomics, metatranscriptomics & RNA seq… to get some idea of the pathogenesis of LC at the site of initial infection.”
March 11, 2025 at 7:41 PM
Dr. David Price is investigating the role of lung dysfunction in Long Covid: “We’re sampling bronchoalveolar lavage fluid and transbronchial biopsies… what we plan to do is metagenomics, metatranscriptomics & RNA seq… to get some idea of the pathogenesis of LC at the site of initial infection.”
Dr. Petter Brodin is leading a project investigating the genetic determinants of Long Covid. “We’re currently looking for genetic variants that could explain why [Long Covid patients] have what we think is impaired antiviral immunity, leading to viral persistence.”
March 8, 2025 at 12:20 AM
Dr. Petter Brodin is leading a project investigating the genetic determinants of Long Covid. “We’re currently looking for genetic variants that could explain why [Long Covid patients] have what we think is impaired antiviral immunity, leading to viral persistence.”
Dr. Akiko Iwasaki, who has led work on the role of human endogenous retroviruses (HERVs) in chronic diseases i.e. lupus, is now investigating the role of HERVs in Long Covid.
March 5, 2025 at 6:31 PM
Dr. Akiko Iwasaki, who has led work on the role of human endogenous retroviruses (HERVs) in chronic diseases i.e. lupus, is now investigating the role of HERVs in Long Covid.